How does this study impact clinical practice?

• Patients with HF are at higher risk of death, recurrent hospitalisations, debilitating symptoms, physical limitations, and poor quality of life.⁷
• Collating data from all large outcome trials show SGLT-2 inhibitors to reduce the risk of CV death and hospitalisations for HF with reduced EF, HF with preserved EF, and patients hospitalised irrespective of EF (diabetes status had no impact),⁸ and displayed a favourable safety profile vs placebo.⁹
• SGLT2 inhibitors:^9–13
  • Improve haemodynamics and are good decongestants in patients with a classical clinical syndrome of HF.
  • Have a positive effect on LV remodelling, myocardial energetics, metabolomics, and nephroprotection
  • Are beneficial for all HF irrespective of EF.